Assessment of the impact of pharmacist-led intervention with antibiotics in patients with bone and joint infection

Infect Dis Now. 2023 Sep;53(6):104671. doi: 10.1016/j.idnow.2023.104671. Epub 2023 Feb 2.

Abstract

Objectives: The management of patients with bone and joint infections (BJIs) is complex. To improve this care, we carried out pharmaceutical actions in the orthopedic unit, including pharmacist-led-intervention (PLI) for patients requiring prolonged antibiotics. Few data exist regarding patient compliance, adherence and knowledge in cases of BJI. Data on hospital readmission are likewise limited, even though it is considered as a major determinant of clinical impact. The aim of this study was to assess the effectiveness of PLI regarding six-month readmissions.

Patients and methods: Patients were assigned to two groups, both receiving standardized care. Two periods were compared: control group (CG) without PLI and interventional group (IG) with PLI throughout. The analysis was based on patient records and included: proportion of rehospitalizations at 6 months for infectious causes, reasons for antibiotic dose modification or antibiotic switch after 6 weeks, and descriptive analysis of data on pharmaceutical interventions in care pathways.

Results: Analysis was performed on 164 patients: 105 CG (64 %) patients and 59 IG (36 %) patients. There were no significant differences between IG and CG in patients' socio-demographic characteristics, infectious factors and antibiotic regimens. Amongst the CG patients, 23 were readmitted (22 %) versus 3 patients in the IG (5 %), (p = 0.002). There were significantly fewer treatment changes after 6 weeks (28.6 % versus 15.3 %, p = 0.05) for IG patients.

Conclusion: In this retrospective survey, our results suggest a positive impact of PLI on 6-month readmission for all causes in BJI patients. These results need to be confirmed in a multicentric study.

Keywords: Antibiotic; Bone and joint infections; Multidisciplinary support; Pharmacist-led intervention; Readmission.

MeSH terms

  • Anti-Bacterial Agents* / therapeutic use
  • Humans
  • Pharmaceutical Preparations
  • Pharmacists*
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents
  • Pharmaceutical Preparations